Margarita Codinach

Dr. Margarita Codinach


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2019 in Cells
Verified
Journal Article
Open access
PDF file
MGMARTA GRAU-VORSTER
MARTA GRAU-VORSTER
LRLuciano Rodríguez
Luciano Rodríguez
AMAnna del Mazo-Barbara
Anna del Mazo-Barbara
CMClémentine Mirabel
Clémentine Mirabel
MBMargarita Blanco Blanco
Margarita Blanco Blanco
JVJoaquim Vives
Joaquim Vives
Background: The selection of assays suitable for testing the potency of clinical grade multipotent mesenchymal stromal cell (MSC)-based products and its interpretation is a challenge for both developers and regulators. Here, we present a bioprocess design for the production of Wharton’s jelly (WJ)-derived MSCs and a validated immunopotency assay approved by the competent regulatory authority for batch release together with the study of failure modes in the bioprocess with potential impact on critical quality attributes (CQA) of the final product. Methods: The lymphocyte proliferation assay was used for determining the immunopotency of WJ-MSCs and validated under good manufacturing practices (GMP). Moreover, failure mode effects analysis (FMEA) was used to identify and quantify the potential impact of different unexpected situations on the CQA. Results: A production process based on a two-tiered cell banking strategy resulted in batches with sufficient numbers of cells for clinical use in compliance with approved specifications including MSC identity (expressing CD73, CD90, CD105, but not CD31, CD45, or HLA-DR). Remarkably, all batches showed high capacity to inhibit the proliferation of activated lymphocytes. Moreover, implementation of risk management tools led to an in-depth understanding of the manufacturing process as well as the identification of weak points to be reinforced. Conclusions: The bioprocess design showed here together with detailed risk management and the use of a robust method for immunomodulation potency testing allowed for the robust production of clinical-grade WJ-MSCs under pharmaceutical standards.

29 April 2023 in Immunologic Research
Verified
Journal Article
Open access
PDF file
STSílvia Torrents
Sílvia Torrents
AMAndrés Escudero del Moral
Andrés Escudero del Moral
MCMargarita Codinach
Margarita Codinach
LRLuciano Rodríguez
Luciano Rodríguez
SGSergi Querol Giner
Sergi Querol Giner
JVJoaquim Vives
Joaquim Vives
Multipotent mesenchymal stromal cells (MSC) offer new therapeutic opportunities based on their ability to modulate an imbalanced immune system. Immunomodulatory potency is typically demonstrated in vitro by measuring the presence of surrogate markers (i.e., indoleamine-2,3-dioxygenase, IDO; tumor necrosis factor receptor type 1, TNFR1) and/or functional assays in co-cultures (i.e., inhibition of lymphoproliferation, polarization of macrophages). However, the biological variability of reagents used in the latter type of assays leads to unreliable and difficult to reproduce data therefore making cross-comparison between batches difficult, both at the intra- and inter-laboratory levels. Herein, we describe a set of experiments aiming at the definition and validation of reliable biological reagents as a first step towards standardization of a potency assay. This approach is based on the co-culture of Wharton’s jelly (WJ)-derived MSC and cryopreserved pooled peripheral blood mononuclear cells. Altogether, we successfully defined a robust and reproducible immunopotency assay based on previously described methods incorporating substantial improvements such as cryopreservation of multiple vials of pooled peripheral blood mononuclear cells (PBMC) from 5 individual donors that enable a number of tests with same reagents, also reducing waste of PBMC from individual donors and therefore contributing to a more efficient and ethical method to use substances of human origin (SoHO). The new methodology was successfully validated using 11 batches of clinical grade MSC,WJ. Methods described here contribute to minimize PBMC donor variability while reducing costs, streamlining assay setup and convenience and laying the foundations for harmonization of biological reagents usage in standardized immunopotency assays for MSC. Highlights: • The use of pools of peripheral blood mononuclear cells (PBMCs) in potency assays contributes to robust and reproducible results, which is key in the assessment of mesenchymal stroma cells (MSC) potency for batch release. • Cryopreservation of PBMCs does not impact negatively on their activation and proliferation abilities. • Cryopreserved pools of PBMC constitutes convenient off-the-shelf reagents for potency assays. • Cryopreservation of pooled PBMCs from multiple donors is a way to reduce waste of donated PBMC and its associated costs, as well as reducing the impact of individual donor variability of substances of human origin (SoHO).

9 May 2024 in American Journal of Transplantation
Verified
Journal Article
Open access
ASAbiu Sempere
Abiu Sempere
NCNerea Castillo
Nerea Castillo
FRFrancesc Rudilla
Francesc Rudilla
SGSergi Querol Giner
Sergi Querol Giner
EEEmma Enrich
Emma Enrich
MBMarta Bodro
Marta Bodro
The strategy for Progressive Multifocal Leukoencephalopathy (PML) in Solid Organ Transplant recipients primarily focuses on reducing immunosuppressive therapy. However, this approach offers limited efficacy and carries a high risk of graft loss. Here, we present the case of a 64-year-old male kidney transplant recipient with a high degree of immunosuppression who developed PML in October 2022. Despite standard reduction of immunosuppressive therapy, the patient's condition continued to deteriorate, as evidenced by worsening neurological symptoms and increasing JC virus DNA levels in cerebrospinal fluid. This prompted the innovative use of BKPyV -specific T Cells-(BKPyV -VST) therapy, given the genetic similarities between BK and JC viruses. Infusion of third-party donor BKPyV -VST resulted in clinical stabilization, significant reduction in JCV DNA levels, and the emergence of a JC virus-specific T cell response, as observed in ELISpot assays and TCRβ sequencing. This represents the first case report of successful third-party BKPyV -VST -specific therapy in a kidney recipient presenting PML, without graft-versus-host disease or graft dysfunction.

26 March 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
FBFernando Martins Braga
Fernando Martins Braga
HKHatice Kumru
Hatice Kumru
JPJesús Benito Penalva
Jesús Benito Penalva
JVJoaquim Vives
Joaquim Vives
RBRuth Coll Bonet
Ruth Coll Bonet
JVJoan Vidal
Joan Vidal
Background/Objectives: Chronic traumatic spinal cord injury (SCI) causes persistent neurological deficits for which no clinically effective regenerative therapy is currently available. Mesenchymal stromal/stem cells (MSCs), particularly Wharton’s jelly-derived MSCs (WJ-MSCs), demonstrate immunomodulatory and neurotrophic potential. This phase I/II study evaluated the safety and efficacy of intrathecal allogeneic WJ-MSC administration in individuals with chronic incomplete cervical SCI. Methods: In this multicentre, randomised, double-blind, placebo-controlled trial (NCT05054803, EudraCT 2021-000346-18), 18 participants with chronic (1–5 years post-injury) incomplete cervical SCI (AIS B–D) received two intrathecal injections of WJ-MSCs (0.7–1.3 × 106 viable cells/kg) or a placebo at baseline and 3 months. Seventeen participants completed the 12-month follow-up. Primary outcomes assessed safety, and secondary endpoints included International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) motor and sensory scores, spasticity, neuropathic pain, functional independence, neurophysiological measures, and quality of life. Results: Intrathecal WJ-MSC administration was safe and well tolerated. Eighty adverse events occurred (placebo: 26; WJ-MSC: 54), predominantly mild or moderate; four severe events were unrelated to treatment. Both groups demonstrated significant within-group improvements in total motor scores at 12 months, with no between-group difference. No treatment effects were observed for sensory scores, electrophysiological measures, functional independence, spasticity, pain, or patient-reported outcomes. Conclusions: In this first randomised, placebo-controlled trial evaluating intrathecal WJ-MSCs in chronic incomplete cervical SCI, WJ-MSC administration demonstrated a favourable safety profile; however, no significant between-group differences were detected relative to the placebo. Given the limited sample size and early-phase design, the efficacy findings should be interpreted cautiously. Future research should explore enhanced cell products, intensified dosing schedules, optimised delivery strategies, early intervention, and multimodal therapeutic combinations.

10 May 2023 in Cytotherapy
Verified
Journal Article
Closed access
ALA. López-Fernández
A. López-Fernández
MCMargarita Codinach
Margarita Codinach
MCM. Coca
M. Coca
JCJ. Castaño
J. Castaño
CPCristina Prat-Vidal
Cristina Prat-Vidal
JVJoaquim Vives
Joaquim Vives

31 January 2026 in Transfusion
Verified
Journal Article
Open access
GAGemma Aran
Gemma Aran
STSilvia Torrents
Silvia Torrents
MBMargarita Blanco
Margarita Blanco
NSNicole Somarriba
Nicole Somarriba
FAF. Javier Algar
F. Javier Algar
MCMargarita Codinach
Margarita Codinach
Background: Accurate quantification of residual leukocytes (rWBC) and red blood cells (rRBC) in leukoreduced blood components is essential to ensure product quality and transfusion safety. Conventional manual flow cytometry techniques are time‐consuming and analyst‐dependent. In this study, we validated the XN‐1000 Blood Bank (BB) mode as an automated alternative and compared its performance with our standard quality control (QC) workflow. Study Design and Methods: The BB mode was validated for precision, linearity, and carry‐over in detecting residual cells in red blood cell concentrates, platelet concentrates, and plasma products. Results obtained were compared to those of manual flow cytometry (for rWBC and rRBC) and impedance‐based hematology analysis (for platelet counts) across over 1000 blood components. Results: Methods validation showed high linearity, acceptable precision at low cell concentrations, and no analytical interference. Comparison between workflows revealed similar results for hemoglobin, hematocrit, and leukocyte counts. rRBC values measured by BB mode were ~2.3‐fold higher than those obtained by manual flow cytometry, although all values remained within product specifications. Platelet counts were consistently higher with BB mode (PLT‐F) than with impedance, with a 15–51% increase depending on the product. Flow cytometry confirmed that PLT‐F results better reflect the true platelet content than impedance. Conclusion: The XN‐1000 BB mode is a reliable and efficient alternative to manual methods for QC monitoring of blood components. It offers accurate residual cell quantification, increases laboratory throughput, and simplifies workflows.